GLP-1 drugs like Ozempic/Wegovy don’t increase a person’s risk of suicidal actions or thoughts, a new study has conclu ...

In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer for Pleio, shares some best practices on finding trustworthy and verified information about a new prescription or ...

On a micro level, there are many factors that can influence food noise. Genetics, for one, may play a role, says Dr. Kumar. Alternately, the food habits and attitudes instilled in ...

Diabetes and obesity are growing health concerns worldwide. A type of medication called GLP-1 receptor agonists, commonly ...

Artificial intelligence tools continue to be a focal point among publicly traded digital health companies looking to improve ...

Biocon will market Liraglutide under two brand names - Liraglutide Biocon for diabetes, which is a generic version of Victoza ...

If you’re a Queer Eye fan, then you know and love Jonathan Van Ness, the show’s bubbly hairstylist known to share their words ...

Biotechnology firm Biocon on Friday said it has launched a product for diabetes and obesity management in the UK.

This launch follows the nod from the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA), making Biocon the ...

Sara Burnett, executive director of non-profit ReFED, on food waste in the US, government policies, and the impact of AI and ...

Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes and obesity, in the United Kingdom (U.K.). The drug-device combination will be marketed in the U.K. under the brand names ...

Companies such as PepsiCo and Mondelēz haven’t seen an impact on business, while Healthy Choice maker Conagra sees the ...